Opin vísindi

Nordic treatment practices survey and consensus for treatment of eyelid sebaceous carcinoma

Show simple item record

dc.contributor Háskóli Íslands
dc.contributor University of Iceland
dc.contributor.author Leivo, Tiina
dc.contributor.author Sarmela, Johanna
dc.contributor.author Enckell-Aaltonen, Maria
dc.contributor.author Dafgård Kopp, Eva
dc.contributor.author Schmitt, Caroline
dc.contributor.author Toft, Peter B.
dc.contributor.author Sigurðsson, Haraldur
dc.contributor.author Uusitalo, Marita
dc.date.accessioned 2021-01-19T14:04:42Z
dc.date.available 2021-01-19T14:04:42Z
dc.date.issued 2020-03-16
dc.identifier.citation Leivo, T., Sarmela, J., Enckell-Aaltonen, M. et al. Nordic treatment practices survey and consensus for treatment of eyelid sebaceous carcinoma. BMC Ophthalmol 20, 103 (2020). https://doi.org/10.1186/s12886-020-01367-3
dc.identifier.issn 1471-2415
dc.identifier.uri https://hdl.handle.net/20.500.11815/2395
dc.description Publisher's version (útgefin grein)
dc.description.abstract Background: The purpose was to describe the Nordic treatment practices and to reach a Nordic consensus for the treatment of sebaceous eyelid carcinoma. Methods: The treatment practices data was collected by a questionnaire with 37 questions to the Nordic oculoplastic surgeons and analyzed. A PubMed MEDLINE database search was done to gather data on the published treatment practices and recommendations. A working group that consisted of in minimum one senior consultant from each leading Nordic University Eye Hospital was assigned. A structured interactive method was used to establish the consensus. Results: Twenty-four doctors responded to the questionnaire. 23/24 (96%) of the respondents took a biopsy before surgery. Regional lymph node scanning was routinely done by 14/23 (61%) and a systemic screening of a metastatic disease by 13/23 (57%). 6/22 (27%) never took conjunctival mapping biopsies and 12/23 (52%) never screened for Muir-Torre. Respondents used Mohs surgery, frozen section or multi-stage excision with delayed closure, and 5-6 mm was the mostly preferred margin. Sentinel lymph node biopsy was a possible option for 9/22 (41%) and cryotherapy and Mitomycin C for 6/22 (27%) respondents. 50% of respondents considered radiation as a treatment option. 15/16 (94%) respondents always followed-up their patients, most for 5 years. Two thirds scanned regional lymph nodes during the follow-up. Consensus was reached for 18 statements representing three domains: Preoperative work-up, treatment and follow-up. Conclusion: Treatment practices differ in between the five Nordic countries which have similar public health care systems. In the article the authors present a Nordic consensus for the treatment of eyelid sebaceous carcinoma.
dc.description.sponsorship Evald ja Hilda Nissi Foundation. The funder had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
dc.format.extent 103
dc.language.iso en
dc.publisher Springer Science and Business Media LLC
dc.relation.ispartofseries BMC Ophthalmology;20(1)
dc.rights info:eu-repo/semantics/openAccess
dc.subject Consensus
dc.subject Eyelid
dc.subject Nordic
dc.subject Sebaceous carcinoma
dc.subject Treatment
dc.subject Augnlækningar
dc.title Nordic treatment practices survey and consensus for treatment of eyelid sebaceous carcinoma
dc.type info:eu-repo/semantics/article
dcterms.license Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
dc.description.version Peer Reviewed
dc.identifier.journal BMC Ophthalmology
dc.identifier.doi 10.1186/s12886-020-01367-3
dc.contributor.department Læknadeild (HÍ)
dc.contributor.department Faculty of Medicine (UI)
dc.contributor.school Heilbrigðisvísindasvið (HÍ)
dc.contributor.school School of Health Sciences (UI)


Files in this item

This item appears in the following Collection(s)

Show simple item record